Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Encorafenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 67,108Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer angles Braftovi combo for full FDA approval
    Pfizer angles Braftovi combo for full FDA approval

    04 Feb 2025

    // PRESS RELEASE

    https://www.pfizer.com/news/press-release/press-release-detail/pfizers-braftovir-combination-regimen-significantly

    PRESS RELEASE
    04 Feb 2025
    Share Share
    Pfizer’s BRAFTOVI Boosts Response In Mutant Colorectal Cancer
    Pfizer’s BRAFTOVI Boosts Response In Mutant Colorectal Cancer

    27 Jan 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/pfizers-braftovi-combination-demonstrates-improved-response-for-mutant-metastatic-colorectal-cancer-16710

    INDPHARMAPOST
    27 Jan 2025
    Share Share
    FDA Approves Pfizer’s Braftovi for 1st-Line Treat Colorectal Cancer
    FDA Approves Pfizer’s Braftovi for 1st-Line Treat Colorectal Cancer

    20 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241210321033/en

    BUSINESSWIRE
    20 Dec 2024
    Share Share
    Pfizer's BRAFTOVI + MEKTOVI Shows Long-Term Response In NSCLC
    Pfizer's BRAFTOVI + MEKTOVI Shows Long-Term Response In NSCLC

    14 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240913128678/en

    BUSINESSWIRE
    14 Sep 2024
    Share Share
    Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
    Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

    24 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/24/2869078/0/en/Erasca-Announces-Three-Presentations-at-the-2024-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    24 Apr 2024
    Share Share
    EMA validates Pierre Fabre's MAA for BRAFTOVI
    EMA validates Pierre Fabre's MAA for BRAFTOVI

    02 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/european-medicines-agency-validates-pierre-fabre-laboratories-marketing-authorisation-application-for-combination-braftovi-encorafenib-and-mektovi-binimetinib-for-patients-with-brafv600-mutant-advanced-non-small-cell-lung-c-301975614.html

    PR NEWSWIRE
    02 Nov 2023
    Share Share